Post-Conference Perspectives: Managing R/R B-ALL with CAR T-Cell Therapy - Episode 7

The Future of R/R B-ALL Treatment

Jae Park, MD, wraps up his discussion by highlighting exciting investigational agents on the horizon for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

EP. 1: Signs and Symptoms of B-Cell Acute Lymphoblastic Leukemia (B-ALL)
EP. 2: Available Treatment Options for Patients With Relapsed/Refractory (R/R) B-ALL
EP. 3: R/R B-ALL: Key Efficacy Outcomes From the Updated Analysis of the ZUMA-3 Trial
EP. 4: R/R B-ALL: Key Safety Outcomes From the Updated Analysis of the ZUMA-3 Trial
EP. 5: Outcomes Data Following Brexucabtagene Autoleucel Therapy in Patients With R/R B-ALL
EP. 6: An Oncologist’s Experience With Treating R/R B-ALL With Brexucabtagene Autoleucel in Clinical Practice
Now Viewing
EP. 7: The Future of R/R B-ALL Treatment